Meloxicam Tablet
Product Images NDC 71610-872

This text provides important information about the risks associated with the use of NSAIDs (nonsteroidal anti-inflammatory drugs). It highlights that increasing doses and prolonged use of NSAIDs can lead to potential complications. Additionally, it warns against taking NSAIDs before or after a heart surgery known as a coronary artery bypass graft (CABG) and advises against using them after a recent heart attack due to the increased risk of further heart issues. It emphasizes the significance of consulting a healthcare professional before using NSAIDs in such situations.*

This text highlights important warnings related to the use of NSAIDs (Nonsteroidal anti-inflammatory drugs), including the risk of ulcers, bleeding, and potentially fatal complications. Factors increasing the risk include past history of ulcers or bleeding, use of specific medications, increasing NSAID doses, longer use, smoking, alcohol consumption, older age, poor health, liver disease, and bleeding disorders. It emphasizes the importance of being aware of these risks and monitoring for warning symptoms while using NSAIDs.*

This text appears to provide information on symptoms related to health issues. It mentions signs like shortness of breath, slurred speech, chest pain, swelling of the face or throat, and weakness in one part or side of the body. These symptoms can indicate various medical conditions and may require urgent medical attention.*

This text outlines various symptoms related to health issues, such as nausea, tiredness, diarrhea, itching, yellowish skin or eyes, indigestion, flu-like symptoms, vomiting blood, blood in bowel movements, unusual weight gain, skin rash with fever, and swelling in limbs. These symptoms might indicate underlying health concerns and should be further evaluated by a healthcare professional.*

This text provides a table with Adverse Events (%) occurring in 22% of Meloxicam patients during an osteoarthritis placebo- and active-controlled trial. It includes information on the number of patients and the occurrence of various adverse events such as gastrointestinal issues, abdominal pain, diarrhea, edema, falls, influenza-like symptoms, dizziness, headache, respiratory problems, and skin rash. The table shows comparative data between placebo, Meloxicam (15mg daily and 7.5mg twice daily), and Diclofenac (100mg daily) treatments.*

This is a table showing the adverse events (%) occurring in more than 2% of Meloxicam patients in two 12-week Rheumatoid Arthritis Placebo-Controlled Trials. The data includes the number of patients, types of adverse events such as gastrointestinal disorders, abdominal pain, dyspeptic signs and symptoms, influenza-like illness, infection and infestations, musculoskeletal and connective tissue disorders, nervous system disorders, and skin and subcutaneous reactions. The table also provides MedDRA high-level terms and preferred terms for some adverse events like dyspeptic signs and symptoms, upper respiratory tract infections, joint-related signs and symptoms, nausea, abdominal pain, influenza-like illness, headaches, and rash.*

This text appears to be a list of potential side effects or symptoms associated with a particular medication or medical condition. It includes categories such as Body as a Whole, Cardiovascular, Central and Peripheral Nervous System, Gastrointestinal, Heart Rate and Rhythm, Hematologic, Liver and Biliary System, Metabolic and Dehydration, Nutritional, Psychiatric, Respiratory, Skin and Appendages, Special Senses, and Urinary System. Each category lists various symptoms or conditions that may occur in relation to the medication or condition being discussed. The text provides a comprehensive overview of potential reactions or effects that individuals may experience.*

This information provides a detailed breakdown of adverse events occurring in more than 2% of patients taking Meloxicam in 4 to 6-week and 6-month active-controlled osteoarthritis trials. The table shows the percentage of events such as gastrointestinal issues, abdominal pain, diarrhea, vomiting, dizziness, headache, anemia, back pain, insomnia, respiratory problems, and urinary tract infections among others. Additionally, it combines WHO preferred terms for conditions like edema and rash for more concise reporting.*

This text provides essential information on potential drug interactions with Meloxicam, an NSAID. It highlights the clinical impacts of combining Meloxicam with lithium, methotrexate, cyclosporine, pemetrexed, and other NSAIDs/salicylates. For each combination, it specifies the intervention needed to monitor and manage potential toxicities and risks. The text suggests close monitoring for signs of toxicity and adjusting dosages to mitigate adverse effects when using Meloxicam concurrently with these medications. This detailed guidance aims to ensure patient safety and treatment effectiveness when using Meloxicam in combination with other drugs.*

This text discusses clinically significant drug interactions with Meloxicam that healthcare professionals need to be aware of. It highlights the impact of the concomitant use of Meloxicam with drugs that interfere with hemostasis, such as anticoagulants, antiplatelet agents, and serotonin reuptake inhibitors, leading to an increased risk of bleeding. The text also emphasizes the importance of monitoring patients for signs of bleeding when using Meloxicam with these medications. Additionally, it mentions the potential decreased efficacy of ACE inhibitors, angiotensin receptor blockers, or beta-blockers when taken with NSAIDs like Meloxicam, especially in elderly or volume-depleted patients. The need to monitor blood pressure and renal function during concomitant use is stressed. Lastly, the text touches on how NSAIDs can affect the natriuretic effect of diuretics and the importance of observing patients for signs of renal function worsening during the combined use of Meloxicam and diuretics.*

This is a description of Table 4 which presents the single dose and steady-state pharmacokinetic parameters for oral 7.5 mg and 15 mg Meloxicam, showing the mean and % CV. The table displays the data for different dosages and formulations (tablets and capsules) of Meloxicam. The parameters provided in the table are from various studies conducted under normal conditions, not under high-fat conditions.*